SHANGHAI and CAMBRIDGE,
Mass. and REYKJAVIK, Iceland,
Sept. 16, 2015 /PRNewswire/
-- WuXi NextCODE, a precision medicine company using the
genome to improve health worldwide, and the Children's Hospital of
Fudan University (CHFU), based in Shanghai and serving 2.3 million patients
nationwide per year, today announced the signing of a landmark
agreement for advancing precision medicine in China. It brings WuXi NextCODE's renowned
genomic testing capabilities directly into clinical use for the
first time in China, and builds on
CHFU's preeminence in pediatrics to begin immediately to deliver
benefits to thousands of rare disease patients across China.
![Leading Genomics Leading Genomics](http://photos.prnewswire.com/prnvar/20150325/194344LOGO)
WuXi NextCODE is deploying the full range of its renowned genome
testing infrastructure for CHFU: CLIA sequencing, massively
scalable informatics, and the most powerful interpretation tools
and clinical genetics expertise. As a result, CHFU will be able to
offer Chinese rare disease patients the same sequence-based
diagnostics now available to patients in the United States and Europe through partners including Boston
Children's Hospital and Genomics England. CHFU, which sees as many
as 7,000 patients every day, can now rapidly scale up
sequence-based testing to resolve more undiagnosed cases.
"We share a mission with CHFU: to put the best technology in the
hands of the best doctors and scientists to help patients," said Dr
Ge Li, Chairman and CEO of WuXi
AppTec, of which WuXi NextCODE is a wholly owned subsidiary. "We
are very excited to join with our friends at CHFU to take the lead
in rare disease diagnosis, care and research in China, offering patients world-class testing
right here."
"Looking for the genomics infrastructure that could deliver the
best results for our patients, we saw that our colleagues at
Harvard Medical School and other
leading institutions were choosing WuXi NextCODE," said
Guoying Huang, President of CHFU.
"We've come to the same conclusion. Using the emerging global
standard for genomic data in medicine, we can move beyond static
gene panels to employ the full power of the genome to address rare
diseases, genetic and genetics-related disorders and eventually
cancer and other conditions as well. We can also collaborate
instantly with sister institutions that use WuXi NextCODE's system
to push the frontiers of care and discovery."
"Our aim is to bring our technology into the clinic to deliver
precision medicine to patients in every market worldwide," said
Hannes Smarason, co-founder, President and COO of WuXi NextCODE.
"China is central to that
strategy, and we couldn't have a better partner than Fudan
Children's for realizing it and giving thousands of young patients
and their families the best diagnostics and treatment options for
inherited rare disorders."
WuXi NextCODE offers uniquely comprehensive and
integrated capabilities for using the genome to better diagnose
disease and create better medicine. These include a full range of
sequencing services through our CLIA-certified laboratory; the
world's leading genome interpretation system; a novel database
architecture that makes it possible to query, manage, store and
share massive genomic data with unrivalled speed and efficiency;
and the know-how and experience to apply genomics to optimize every
aspect of drug discovery and development. With offices in
Shanghai; Cambridge, Massachusetts; and Reykjavik, Iceland, we enable clinicians and
researchers at institutions and companies worldwide to use the full
power of the genome to deliver precision medicine and support
health. WuXi NextCODE is a wholly owned subsidiary of WuXi AppTec,
the operating subsidiaries of WuXi PharmaTech (NYSE: WX). WuXi
AppTec comprises a leading open-access R&D capability and
technology platform company serving the pharmaceutical,
biotechnology, and medical device industries, with operations in
China and the United States.
Fudan University Children's Hospital.
Children's Hospital of Fudan University is a prestigious
tertiary academic medical center for children in China. Since its founding in 1952, it has been
dedicated to providing pediatric patient care, education and
research. CHFU is designated by the Ministry of Education as a key
national center for pediatrics. It provides training programs for
masters and doctoral degrees, as well as postdoctoral fellowships.
CHFU has consistently led the field in China through the comprehensiveness of its
capabilities. Its Institute for Pediatric Research has developed
more than 100 tests for single-gene genetic diseases, established
multidisciplinary teams of clinical experts, and is among the very
first hospitals to adopt next generation sequencing. CHFU is a
pioneer in the clinical diagnosis of genetic diseases in
China.
Contacts:
|
|
|
|
WuXi
NextCODE
|
WuXi
AppTec
|
Edward
Farmer
|
Aaron Shi
|
VP Communications
& New Ventures
|
Director of Corporate
Communications
|
efarmer@wuxinextcode.com
|
aaron_shi@wuxiapptec.com
|
+1 781 775 6206
|
+86-21
5046-4362
|
|
|
Children's Hospital
of Fudan University
|
Liling
Qian
|
Director of
Administrative Office, Institute for Pediatric Research
|
Children's Hospital
of Fudan University
|
ekyykyb@163.com
|
+86-21
6493-1913
|
Logo - http://photos.prnewswire.com/prnh/20150325/194344LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/wuxi-nextcode-and-fudan-childrens-hospital-partner-to-lead-whole-genome-diagnostics-for-rare-diseases-in-china-300143708.html
SOURCE WuXi NextCODE